Valiant Laboratories dispatched physical letters on September 3, 2026, to shareholders who have not registered their email addresses. The correspondence provides access to the Annual Report for FY26 and the Notice for the fifth Annual General Meeting scheduled for September 28, 2026.

The company notified the BSE and NSE regarding this dispatch under Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action ensures that all members, including those without digital contact details, receive information about the upcoming gathering.

Meeting Logistics

Valiant Laboratories will hold its fifth Annual General Meeting on September 28, 2026, at 11:30 am via Video Conferencing or Other Audio Visual Means. The company previously notified exchanges on August 31, 2026, about these logistics. Shareholders with registered emails received the documents electronically.

Physical letters were sent to members as on August 28, 2026, who lacked registered emails with the company, MUFG Intime India Private Limited, or their Depository Participants. These letters contain a web-link to access the documents on the company’s website.

Document Access and Updates

Members can access the Annual Report and AGM Notice through the following path on the company website: www.valiantlabs.in > Investors > Financial Information > Annual Report > Annual Report 2026. The documents are also available on the BSE and NSE portals.

Shareholders holding shares in physical mode are requested to submit KYC forms to MUFG Intime India Private Limited to register their email addresses. Those with demat shares should update their details with their Depository Participants.

Voting Procedures

National Securities Depository Limited is facilitating remote e-voting for the meeting. Shareholders can cast votes on all resolutions either remotely or during the meeting. Queries regarding the voting process can be directed to NSDL at evoting@nsdl.co.in .

Valiant Laboratories reported a standalone net profit of ₹9.48 crore for the quarter ended June 30, 2026, a 422% increase from ₹1.82 crore in the corresponding period of FY25. The Mumbai-based pharmaceutical company also saw its revenue from operations surge 44% year-on-year to ₹74.27 crore, up from ₹51.68 crore in Q1FY26. Consolidated net profit turned positive at ₹21.10 crore, reversing a loss of ₹3.27 crore recorded in the prior year quarter.

The results were reviewed by the Audit Committee and approved by the Board of Directors in a meeting held on August 10, 2026. The financial statements were prepared in accordance with Indian Accounting Standards (IndAS) prescribed under Section 133 of the Companies Act, 2013, and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published these audited results in Financial Express and Mumbai Lakshadeep on August 12, 2026, as required under Regulation 30 and Regulation 47 of SEBI LODR.

Financial Performance

Standalone earnings per share (EPS) stood at ₹1.75 for the quarter, compared to ₹0.42 in Q1FY26. On a consolidated basis, EPS was ₹3.89, improving from ₹0.42 in the previous year. The company’s paid-up equity share capital remained unchanged at ₹54.31 crore.

What the Numbers Show

The divergence between standalone and consolidated performance highlights significant operational leverage in the group structure. While standalone net profit before tax grew five-fold to ₹12.73 crore, consolidated pre-tax profit surged more than ten-fold to ₹26.19 crore. This suggests that subsidiaries or associates contributed disproportionately to the top-line growth, which rose 145% on a consolidated basis compared to 44% standalone. The reversal of consolidated losses into a substantial profit indicates improved efficiency or scale benefits across the group entities during the quarter.